Intelliseq
Michal Korostynski has a diverse work experience spanning various roles and organizations. In 2007, they worked as a Biologist at the Nencki Institute of Experimental Biology, PAS. From 2012, they served as an Expert at The National Centre for Research and Development. In 2013, they became the Chief Scientific Officer at intelliseq, a genome informatics company focused on precision medicine and clinical genetics. Michal also worked as an External Lecturer at Uniwersytet Jagielloński w Krakowie, where they conducted exercises and lectures for students in applied mathematics from 2014 to 2017. Since 2018, they have held multiple roles at Maj Institute of Pharmacology PAS, including Field Editor for Pharmacological Reports, Head of the Laboratory of Pharmacogenomics, and Head of the Technology Transfer Unit.
Michal Korostynski holds a Doctor of Science degree in Medical Science from the Maj Institute of Pharmacology PAS, which they obtained in 2021. Prior to this, they earned a Doctor of Medicinal Sciences degree in Medicinal Biology from the Institute of Pharmacology, PAS from 2003 to 2007. In 2014-2015, they pursued post-graduate studies in Executive MBA at Politechnika Krakowska im. Tadeusza Kościuszki. Earlier, they completed post-graduate studies in Molecular Biology at Jagiellonian University, Krakow, Faculty of Biochemistry, Biophysics, and Biotechnology from 2002 to 2003. Their educational journey began with a Bachelor's degree in Biotechnology from the University of Silesia, Katowice, Faculty of Biology and Environmental Protection, which they obtained from 1997 to 2002.
This person is not in any teams
This person is not in any offices
Intelliseq
Intelliseq is a genome informatics company developing bioinformatics tools for diagnostics, therapy, and prevention based on genetic data. Currently bioinformatics systems in laboratories are not ready for genomics at scale. The analysis process of already sequenced genomes is now mostly expensive and labor-intensive. In response to this problemthe company created a cloud-based platform called IntelliseqFlow that allows for automated bioinformaticianless generation of result reports that accelerates the entire diagnostic process and reduces the costs that the laboratory had to deal with so far. IntelliseqFlow translates raw DNA data into final reports automatically, making the analysis step fast, simple, cost-effective and user-friendly. Allows users to choose ready-to-use workflows for PGx, Germline Disorders, Somatic Cancer, and Polygenic Risk Scoring all wrapped-up in one user-friendly platform. It comprises AI-based algorithms, easy to operate pipelines, customized workflows, and APIs that make it simple to integrate our engine with laboratory information systems.The company was established in 2014 by a group of scientists fascinated with pharmacogenomics and transcriptomics. Intelliseq’s products are currently being used by laboratories in Asia, Europe, and the US.